Cardiovascular Therapeutics最新文献

{"title":"Off-Pump Coronary Artery Bypass Graft (OCABG) Surgery Outcome: AKI Incidence, Serum Uric Acid, and Cut-Offs of Variables","authors":"Mohamad Reza Zare-Khormizi,&nbsp;Fatemeh Pourrajab","doi":"10.1155/2024/5945687","DOIUrl":"https://doi.org/10.1155/2024/5945687","url":null,"abstract":"<p><b>Purpose:</b> One of the most important challenges of the medical community is to find out the success rate of coronary artery bypass surgery and control complications after surgery, including acute kidney injury (AKI). The present study was conducted with the aim of determining the predictive effect of serum uric acid (SUA) (UA) level in patients undergoing off-pump coronary artery bypass (OCABG) surgery.</p><p><b>Methods:</b> The present descriptive-analytical study included 144 patients who underwent OCABG and met the inclusion criteria. SUA and related indicators, duration of hospitalization and stay in ICU, AKI and in-hospital mortality, and 6-month follow-up mortality were investigated.</p><p><b>Results:</b> Patients were divided into high and normal groups based on SUA levels. The prevalence of postoperative AKI was 20% and was significantly associated with the preoperative UA levels (OR: 2.04; CI: 95%; 1.03–4.20). The mortality rate of patients was between 2% and 9%, which increased to 13% in patients with high SUA (<i>p</i> value ~0.224). The average duration of ICU and hospitalization in patients with high UA was longer than the other group (<i>p</i> value ~0.06 and <i>p</i> value ~0.002, respectively).</p><p><b>Conclusion:</b> SUA levels are independently associated with a higher risk of AKI and outcome complications after off-pump CABG, and confounding factors at specific cutoffs affect the odds ratio of UA for AKI occurrence.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5945687","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Designing, Validation, and Feasibility of Integrated Approach of Heartfulness Meditation and Yoga Protocol (IAHFNM & YP) for Hypertensive Participants","authors":"Pooja S. Singh,&nbsp;Veronique Nicolai,&nbsp;Yogesh Patil,&nbsp;Neelam Yeram,&nbsp;Bhusan Bhukte,&nbsp;Kapil Thakur,&nbsp;Mitesh Thakker,&nbsp;Haresh Mehta,&nbsp;Mansee K. Thakur","doi":"10.1155/2024/9289232","DOIUrl":"https://doi.org/10.1155/2024/9289232","url":null,"abstract":"<p>The module was designed and developed at Heartfulness Institute, Kanha Shanti Vanam, Hyderabad. The Department of Medicine, MGM Medical College &amp; Hospital, MGMIHS, Navi Mumbai, carried out the validation and subsequently pilot-tested on volunteers. Forty experts were selected to validate the contents of IAHFNM &amp; YP which was designed after a thorough review of meditation and yoga literature. A total of 23 items were included, and each item was rated as essential or not essential by the experts, based on which the content validity ratio (CVR), Item-Level Content Validity Index (I-CVI), and Scale-Level Content Validity Index Average (S-CVI/Ave) were calculated. Reliability analysis and a pilot study for the feasibility of IAHFNM &amp; YP for hypertensive patients were also done. All 23 practices exhibited significant CVR (≥ 0.29), I-CVI (&gt; 0.79), and S-CVI/Ave (&gt; 0.9); thus, the tool was found to have valid contents. Cronbach’s alpha value for the tool was 0.95 which was highly reliable. Feasibility analysis in hypertensive participants showed that the tool is reliable and implementable. The IAHFNM &amp; YP tool designed for hypertensive patients is valid, reliable, and feasible. The patients showed a willingness to continue with heartfulness meditation and yoga practices for participation in research for a longer duration. Further studies to confirm the tool’s efficacy should be conducted with a large sample size.</p><p><b>Trial Registration:</b>CTRI/2024/01/061035</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/9289232","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Achievement of LDL-Cholesterol Goals in Patients Receiving LLT in Primary Care: TERESA-AP Study","authors":"Sergio Cinza-Sanjurjo,&nbsp;Vivencio Barrios,&nbsp;David Fierro-González,&nbsp;Jose Polo-García,&nbsp;Vicente Pallarés-Carratalá","doi":"10.1155/2024/4227941","DOIUrl":"https://doi.org/10.1155/2024/4227941","url":null,"abstract":"<p><b>Background and Aim:</b> Since 2019, LDL-cholesterol (LDL-C) is the risk factor with the strictest goals and the most difficult to reach, due to its role in the development of atherosclerotic plaque and, therefore, cardiovascular risk. The objective of the TERESA-AP study is to analyze the degree of LDL-C control in patients followed up in primary care with lipid-lowering drug treatment (LLT).</p><p><b>Methods:</b> Observational, multicenter, cross-sectional, nationwide study was conducted, in which 50 PC physicians recruited 929 patients who were receiving LLT during at least the preceding 6 months. The variables required to estimate the patients’ cardiovascular risk and LDL control were recorded.</p><p><b>Results:</b> Nearly half of sample was women (50.5%), and the mean age was 67.8 (10.4) years. High blood pressure (65.3%) and sedentary lifestyle (59.7%) were the most frequent risk factors. Recommended goals were reached in 26.0% (95% CI: 23.3%–29.0%) of patients, with a slightly higher percentage in patients with cardiovascular disease (CVD) (26.7%), diabetes mellitus (DM) (35.5%), and a lower one in patients with chronic kidney disease (CKD) (12.1%). The most frequent drug treatments were statin monotherapy (69.0%) and statin with ezetimibe combination (27.6%), with moderate-intensity statins being the most commonly used in both groups.</p><p><b>Conclusions:</b> On average, only a quarter of the patients followed up in PC and who receive drug treatment reach their therapeutic targets. This percentage is slightly higher if the patients have CVD and DM and lower if they have CKD. The most commonly used therapeutic strategy is moderate-intensity statins, both in monotherapy and in combination with ezetimibe.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4227941","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benzoylaconine: Potential Therapeutic Agent for Cardiovascular Diseases From Fuzi","authors":"Chenggang Xu,&nbsp;Le Tang,&nbsp;Lixin Hu,&nbsp;Yunzhe Huang,&nbsp;Jin Tang,&nbsp;Xiaohu Wang,&nbsp;Feng Wang","doi":"10.1155/2024/4878103","DOIUrl":"https://doi.org/10.1155/2024/4878103","url":null,"abstract":"<p>Modern pharmacological studies have elucidated the presence of aconitine (AC) alkaloids, polysaccharides, and saponins as the primary bioactive constituents of Fuzi. Among these, benzoylaconine, a pivotal active compound, demonstrates notable pharmacological properties including antitumor, anti-inflammatory, and cardiovascular protective effects. In recent years, benzoylaconine has garnered significant attention in basic research on heart diseases, emerging as a focal point of investigation. This paper presents a comprehensive review of the pharmacological effects of benzoylaconine, alongside an overview of advancements in metabolic characterization. The objective is to furnish valuable insights that can serve as a cornerstone for further exploration, utilization, and advancement of benzoylaconine in pharmacological research.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4878103","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Endoplasmic Reticulum Stress-Related Biomarkers in Coronary Artery Disease","authors":"Yuanyuan Lin,&nbsp;Lin Ni,&nbsp;Luqun Yang,&nbsp;Hao Li,&nbsp;Zelin Chen,&nbsp;Yuping Gao,&nbsp;Kaiyi Zhu,&nbsp;Yanni Jia,&nbsp;Zhifang Wu,&nbsp;Sijin Li","doi":"10.1155/2024/4664731","DOIUrl":"https://doi.org/10.1155/2024/4664731","url":null,"abstract":"<p>Coronary artery disease (CAD) is caused by atherosclerotic lesions in the coronary vessels. Endoplasmic reticulum stress (ERS) acts in cardiovascular disease, and its role in CAD is not clear. A total of 13 differentially expressed ERS-related genes (DEERSRGs) in CAD were identified. Functional enrichment analysis demonstrated the DEERSRGs were mainly enriched in endoplasmic reticulum (ER)-related pathways. Then, eight genes (RCN2, HRC, DERL2, RNF183, CRH, TMED2, PPP1R15A, and IL1A) were authenticated as ERS-related biomarkers in CAD by least absolute shrinkage and selection operator (LASSO). The receiver operating characteristic (ROC) analysis showed that the LASSO logistic model constructed based on biomarkers had a better diagnostic effect, which was confirmed by the ANN and GSE23561 datasets. Also, ROC results showed that seven of the eight biomarkers had better diagnostic effects. The nomogram model had good predictive power, and biomarkers were mostly enriched in pathways associated with CAD. The biomarkers were significantly associated with 10 immune cells, and RCN2, DERL2, TMED2, and RNF183 were negatively correlated with most chemokines. Eight biomarkers had significant correlations with both immunoinhibitors and immunostimulators. In addition, eight biomarkers were significantly different in both CAD and control samples, CRH and HRC were upregulated in CAD. The quantitative reverse transcription-polymerase chain reaction (qRT-PCR) showed that RCN2, HRC, DERL2, CRH, and IL1A were consistent with the bioinformatics analysis. RCN2, HRC, DERL2, RNF183, CRH, TMED2, PPP1R15A, and IL1A were identified as biomarkers of CAD. Functional enrichment analysis and immunoassays for biomarkers provide new ideas for the treatment of CAD.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/4664731","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141536639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Diseases Among Indian Older Adults: A Comprehensive Review","authors":"Bisma Jan,&nbsp;Mohammad Imran Dar,&nbsp;Bharti Choudhary,&nbsp;Parakh Basist,&nbsp;Rahmuddin Khan,&nbsp;Abdulsalam Alhalmi","doi":"10.1155/2024/6894693","DOIUrl":"https://doi.org/10.1155/2024/6894693","url":null,"abstract":"<p>Cardiovascular diseases (CVDs) constitute an important cause of morbidity and mortality globally, and India is no exception to this trend. With the ongoing aging of the population in India, there is a notable surge in the prevalence and impact of CVDs among older adults. This review is aimed at providing a comprehensive overview of the current knowledge concerning the prevalence, risk factors, and management of CVDs in the context of Indian older adults. The incidence of CVDs in India is not only alarming but also exhibits an upward trajectory with advancing age. Primary risk factors contributing to the elevated incidence among older adults include hypertension (HT), diabetes, dyslipidemia, obesity, smoking, a sedentary lifestyle, and poor dietary habits. Additionally, stress and genetic predisposition emerge as noteworthy contributors to CVDs in this population. Effectively identifying and managing these risk factors among older adults in India is imperative to alleviate the burden of these diseases and enhance overall quality of life. Strategies aimed at mitigating the impact of CVDs in the country necessitate a comprehensive approach, integrating lifestyle interventions, public health initiatives, and a robust healthcare system. In summary, CVDs represent a significant health concern in both rural and urban areas of India. However, variations exist in the prevalence, risk factors, and accessibility to healthcare between these regions. Therefore, addressing the prevalence of CVDs in India necessitates a complex, multidimensional strategy that takes into account the unique opportunities and challenges that come with living in both rural and urban areas.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/6894693","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141488790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiopulmonary Protection of Modified Remote Ischemic Preconditioning in Mitral Valve Replacement Surgery: A Randomized Controlled Trial","authors":"Lianqin Zhang,&nbsp;Kang Zhou,&nbsp;Tianchu Gu,&nbsp;Jingjing Xu,&nbsp;Mengzhu Shi,&nbsp;Jiang Zhu,&nbsp;Jindong Liu","doi":"10.1155/2024/9889995","DOIUrl":"https://doi.org/10.1155/2024/9889995","url":null,"abstract":"<p><b>Background:</b> Remote ischemic preconditioning (RIPC) is reported to have early-phase and delayed-phase organ-protective effects. Previous studies have focused on the organ protection of a single RIPC protocol, and the clinical outcomes remain uncertain. Whether the modified RIPC (mRIPC) protocol performed repeatedly provides cardiopulmonary protection is still uncertain.</p><p><b>Methods:</b> In this single-center, randomized, controlled trial, 86 patients undergoing elective mitral valve replacement (MVR) surgery were randomized 1:1 to receive either mRIPC or no ischemic preconditioning (control). Three cycles of 5 min ischemia and 5 min reperfusion induced by a blood pressure cuff served as the RIPC stimulus. mRIPC was induced at the following three time points: 24 h, 12 h, and 1 h before surgery. Blood samples were withdrawn at 10 min after intubation (T0), at 1 h after aortic declamping (T1), and at 6 h (T2), 12 h (T3), and 24 h (T4) after surgery to measure the serum concentrations of myocardial enzymes and other biomarkers, including cardiac troponin I (cTnI), which was the primary endpoint of this study. Creatine kinase isoenzyme (CK-MB), lactate dehydrogenase (LDH), inotropic score (IS), and inflammatory mediators were also measured. Blood gas analysis was conducted to calculate the PaO₂/FiO₂ ratio and A-aDO₂, and the incidence of acute lung injury (ALI) was also recorded.</p><p><b>Results:</b> mRIPC significantly decreased the serum concentrations of cTnI, CK-MB, and LDH at T2, T3, and T4 (<i>p</i> &lt; 0.01), and the IS decreased compared with that in the control group (12.0 ± 1.0 vs. 14.2 ± 1.1, <i>p</i> &lt; 0.01). In addition, the incidence of ALI in the mRIPC group was decreased (32.6% vs. 51.2%, <i>p</i> = 0.039), and the PaO₂/FiO₂ was higher at T4 (<i>p</i> &lt; 0.05). Compared with those in the control group, the levels of interleukin-6 (IL-6) and tumor necrosis factor-<i>α</i> (TNF-<i>α</i>) were decreased at T1, T2, T3, and T4 (<i>p</i> &lt; 0.05) in the mRIPC group, and the level of IL-10 increased at the same time.</p><p><b>Conclusions:</b> mRIPC decreased the incidence of myocardial and lung injury in MVR surgery, providing new evidence for the clinical application of RIPC in valve surgery.</p><p><b>Trial Registration:</b> ClinicalTrials.gov (NCT01406678).</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/9889995","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141488363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrial Fibrillation Termination as a Predictor for Persistent Atrial Fibrillation Ablation: A Systemic Review and Meta-Analysis of Prospective Studies","authors":"Jialing He,&nbsp;Zhen Zhang,&nbsp;Duan Luo,&nbsp;Xianchen Yang,&nbsp;Guoshu Yang,&nbsp;Hanxiong Liu","doi":"10.1155/2024/9944490","DOIUrl":"https://doi.org/10.1155/2024/9944490","url":null,"abstract":"<p><b>Background:</b> In this systematic review and meta-analysis, we aimed to validate the predictive role of atrial fibrillation (AF) termination in long-term arrhythmia recurrence.</p><p><b>Method:</b> Our search encompassed databases including MEDLINE, EMBASE, PubMed, and the Cochrane Library up to August 1, 2021. Three independent reviewers conducted screening and data extraction. The data included ablation strategy, recurrence mode, AF termination mode, numbers of patients, and recurrence cases in the termination and nontermination groups. The primary endpoint was the recurrence of atrial arrhythmia at long-term follow-up (≥ 12 months).</p><p><b>Results:</b> Our analysis included 22 publications, with 11 prospective studies being eligible for further meta-analysis. Among these, 14 studies reported significantly lower rates of arrhythmia recurrence in the AF termination group compared to the nontermination group. Among seven studies involving 1114 patients that examined single procedure outcomes, the pooled estimated effect was RR 0.78 (95% CI 0.68–1.90) with an <i>I</i>² value of 57%. Subgroup analysis focusing on termination mode as sinus rhythm yielded a pooled estimated effect of RR 0.74 (95% CI 0.59–0.92) with an <i>I</i>² value of 47%. Additionally, analysis of seven studies involving 1433 patients for repeat procedures demonstrated a significant preference for the AF termination group (RR 0.83, 95% CI 0.71–0.97, <i>I</i>² = 84<i>%</i>). Subgroup analysis indicated reduced heterogeneity when the termination mode was sinus rhythm (RR 0.68, 95% CI 0.51–0.90, <i>I</i>² = 57<i>%</i>).</p><p><b>Conclusion:</b> Our study establishes that AF termination serves as an effective predictor for the success of persistent AF ablation procedures. This finding holds potential implications for clinical practice and contributes to our understanding of long-term arrhythmia recurrence in the context of AF termination.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/9944490","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141439574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atorvastatin Attenuates Endothelial Cell Injury in Atherosclerosis Through Inhibiting ACSL4-Mediated Ferroptosis","authors":"Huilian Tan,&nbsp;Ling Liu,&nbsp;Yanchao Qi,&nbsp;Dahong Zhang,&nbsp;Yanchun Zhi,&nbsp;Yu Li,&nbsp;Huimin Zhang,&nbsp;Jun Liu","doi":"10.1155/2024/5522013","DOIUrl":"https://doi.org/10.1155/2024/5522013","url":null,"abstract":"<p><b>Objective:</b> This study is aimed at investigating the effects of atorvastatin (ATV) on endothelial cell injury in atherosclerosis (AS) through inhibiting acyl-CoA synthetase long-chain family member 4 (ACSL4)-mediated ferroptosis.</p><p><b>Methods:</b> Human umbilical vein endothelial cells (HUVECs) were treated with oxidized low-density lipoprotein (ox-LDL) to establish an in vitro model of AS. The cell viability, lactate dehydrogenase (LDH) release, apoptosis, and expression levels of apoptotic proteins were assessed. The levels of inflammatory factors and adhesion molecules were determined by ELISA and Western blot, respectively. Cellular iron content, lipid peroxidation, glutathione (GSH) levels, and lipid reactive oxygen species (ROS) were measured. ACSL4 overexpression was performed to investigate its role in ATV-mediated protection against ferroptosis.</p><p><b>Results:</b> ATV alleviated ox-LDL-induced HUVEC damage by restoring cell viability, reducing LDH levels, and inhibiting apoptosis. It also attenuated inflammation and adhesion by decreasing the levels of inflammatory factors TNF-<i>α</i>, IL-6, and IL-8, as well as adhesion molecules ICAM-1 and VCAM-1. ATV inhibited ferroptosis by regulating iron content, malondialdehyde (MDA) levels, ROS levels, and ACSL4 protein expression. Overexpression of ACSL4 (oe-ACSL4) hindered the protective effects of ATV on cell viability, antiapoptotic protein expression, LDH levels, apoptosis, and inflammatory factors.</p><p><b>Conclusion:</b> Our findings suggest that ATV attenuates endothelial cell injury in AS by inhibiting ACSL4-mediated ferroptosis. These results provide insights into the potential therapeutic strategies for the treatment of AS.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5522013","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141435619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Shengmai San for Viral Myocarditis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","authors":"Bing-rui Zhang,&nbsp;Xue-han Liu,&nbsp;Yu-tong Ling,&nbsp;Chun-li Lu,&nbsp;Xin-yan Jin,&nbsp;Yi-ming Wei,&nbsp;Yi-qing Cai,&nbsp;Nicola Robinson,&nbsp;Jian-ping Liu","doi":"10.1155/2024/2127018","DOIUrl":"https://doi.org/10.1155/2024/2127018","url":null,"abstract":"<p><b>Background:</b> Shengmai San (SMS) is a traditional Chinese medicine formula used for supplementing <i>Qi</i> and <i>Yin</i> and can mitigate symptoms related to malignant arrhythmia and heart failure. This systematic review aimed at exploring the effectiveness and safety of SMS for viral myocarditis (VMC).</p><p><b>Methods:</b> Eight databases from their inception to June 2023 were searched to identified randomized controlled trials (RCTs) focusing on SMS for VMC. The Cochrane Risk of Bias Tool was used to assess methodological quality. Mean difference (MD), standardized mean difference (SMD), and risk ratio (RR) with 95% confidence interval (CI) were calculated and input into the meta-analysis using RevMan 5.4.</p><p><b>Results:</b> Forty-four RCTs were included involving 4298 participants. The interventions included 29 types of modified SMS decoctions and 15 patent medicines. Overall study quality was low. Compared with western medicine (WM), SMS was associated with higher recovery rate from palpitations (RR 2.3, 95% CI 1.59, 3.33, 2 RCTs, <i>n</i> = 89), chest pain (RR 1.57, 95% CI [1.17, 2.09], 2 RCTs, <i>n</i> = 89), and lower cTnI (MD −0.82 ng/ml, 95% CI −0.98, −0.66, 1 RCT, <i>n</i> = 60). SMS plus WM was more effective than WM in palpitation recovery rate (RR 1.52, 95% CI 1.21, 1.92, 3 RCTs, <i>n</i> = 136), dyspnea recovery rate (RR 1.47, 95% CI 1.12, 1.94, 3 RCT, <i>n</i> = 267), ECG (RR 1.43, 95% CI 1.32, 1.55, 20 RCT, <i>n</i> = 2035), CK-MB (MD −6.36, 95% CI −8.43, −4.28, 8 RCT, <i>n</i> = 946), and cTnI (MD −0.06, 95% CI −0.06, −0.05, 3 RCT, <i>n</i> = 307). No serious adverse events were reported using SMS alone or in combination with WM.</p><p><b>Conclusion:</b> SMS used alone or combined with WM may have potential effectiveness on symptom alleviation, ECG recovery rate, myocardial injury markers, and cardiac function, but the effectiveness is uncertain due to the low quality and absence of placebo-controlled trials. The exact efficacy of SMS for VMC needs to be confirmed by high-quality double-blind RCTs in the future.</p>","PeriodicalId":9582,"journal":{"name":"Cardiovascular Therapeutics","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/2127018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141435618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}